Safe-in-Man Broad Spectrum Antiviral Agents.
Adv Exp Med Biol
; 1322: 313-337, 2021.
Article
in English
| MEDLINE | ID: covidwho-1353664
ABSTRACT
Emerging and re-emerging viral diseases occur with regularity within the human population. The conventional 'one drug, one virus' paradigm for antivirals does not adequately allow for proper preparedness in the face of unknown future epidemics. In addition, drug developers lack the financial incentives to work on antiviral drug discovery, with most pharmaceutical companies choosing to focus on more profitable disease areas. Safe-in-man broad spectrum antiviral agents (BSAAs) can help meet the need for antiviral development by already having passed phase I clinical trials, requiring less time and money to develop, and having the capacity to work against many viruses, allowing for a speedy response when unforeseen epidemics arise. In this chapter, we discuss the benefits of repurposing existing drugs as BSAAs, describe the major steps in safe-in-man BSAA drug development from discovery through clinical trials, and list several database resources that are useful tools for antiviral drug repositioning.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Viruses
/
Virus Diseases
Type of study:
Prognostic study
Limits:
Humans
Language:
English
Journal:
Adv Exp Med Biol
Year:
2021
Document Type:
Article
Affiliation country:
978-981-16-0267-2_12
Similar
MEDLINE
...
LILACS
LIS